Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rapid decrease of free vancomycin in dense staphylococcal cultures.

C Ekdahl1, H Hanberger, A Hällgren

  • 1Division of Infectious Diseases, Department of Molecular and Clinical Medicine, Faculty of Health Sciences, University of Linköping, 581 85, Linköping, Sweden. Christer.Ekdahl@lio.se

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
|September 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence for a Spectral Break or Curvature in the Spectrum of Astrophysical Neutrinos from 5 TeV to 10 PeV.

Physical review letters·2026
Same author

panTB-HM: a multi-arm clinical trial of a pan-TB regimen targeting both host and microbe.

Trials·2026
Same author

Search for Extremely-High-Energy Neutrinos and First Constraints on the Ultrahigh-Energy Cosmic-Ray Proton Fraction with IceCube.

Physical review letters·2025
Same author

Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against <i>Mycobacterium avium</i> in the hollow-fiber system.

Antimicrobial agents and chemotherapy·2025
Same author

Development and Validation of POCOKIDS-Q-A Questionnaire to Assess Post COVID-19 Symptoms in Children.

Acta paediatrica (Oslo, Norway : 1992)·2025
Same author

Measurement of Atmospheric Neutrino Oscillation Parameters Using Convolutional Neural Networks with 9.3 Years of Data in IceCube DeepCore.

Physical review letters·2025

Vancomycin levels decrease rapidly in dense bacterial cultures, increasing minimum inhibitory concentrations (MICs) for Staphylococcus strains. This highlights the importance of vancomycin dosing for serious staphylococcal infections.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Vancomycin is a critical antibiotic for treating Gram-positive bacterial infections.
  • Staphylococcus species, including S. aureus and S. epidermidis, are common pathogens.
  • Bacterial inoculum density can influence antibiotic efficacy and resistance development.

Purpose of the Study:

  • To investigate the impact of bacterial inoculum density on vancomycin broth MICs.
  • To determine free vancomycin concentrations and bacterial viability over time.
  • To assess vancomycin efficacy and resistance emergence in Staphylococcus strains.

Main Methods:

  • Bioluminescence assay used to quantify intracellular bacterial ATP and bacterial numbers.
  • Broth microdilution method to determine vancomycin minimum inhibitory concentrations (MICs).

Related Experiment Videos

  • Agar well bioassay employed to measure free vancomycin concentrations in cultures.

    • Main Results:

    • Vancomycin MICs for Staphylococcus strains increased significantly with higher bacterial inocula (10^5 to 10^8 bacteria/ml).
    • In dense inocula (approx. 10^9-10^10 bacteria/ml), free vancomycin concentrations rapidly decreased below detectable levels (<0.5 microg/ml) within 30 minutes.
    • No emergence of vancomycin resistance was observed in any tested Staphylococcus strains.

    Conclusions:

    • High bacterial loads lead to a rapid reduction in free vancomycin and increased MICs.
    • Vancomycin dosing regimens are crucial for treating staphylococcal infections, especially those with dense bacterial populations like infective endocarditis.
    • The study underscores the need for optimized vancomycin therapy to overcome challenges posed by high bacterial burdens.